Loading company…
SiccaNova Therapeutics develops pharmaceuticals for dryness-related conditions, including dry mouth and dry eye.
Founded in 2022 and based in Ibaraki, Japan, SiccaNova Therapeutics researches small-molecule treatments for dryness-related conditions. Its drug candidate XF8302 is being developed for dry mouth. In September 2026, it raised JPY 1.25 billion in Series A funding from JIC Venture Growth Investments, MPower, Red Capital, 77 Capital, Joyo Capital Partners, and TOHOKU University Venture Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in